Pumen Technology (688389): Continued improvement in performance, significant optimization of product structure
Pumen Technology (688389): Achieving relatively rapid growth in IVD and overseas markets
Pumen Technology (688389): Q2 net profit +39% significant profitability optimization
Pumen Technology (688389): Overseas business growth is impressive, and rehabilitation business is under pressure in the short term
Pumen Technology (688389): Rehabilitation Medicine and Aesthetic+IVD Dual Drive Becoming a Platform Device Company
Pumen Technology (688389): IVD and Treatment and Rehabilitation Qifei Device Platform Company Starts
Pumen Technology (688389): Net profit to mother increased 22% year-on-year in the first quarter of 2024, and new businesses developed rapidly
Cinda Securities released a research report on April 28 stating that it gave Pumen Technology (688389.SH) a buying rating. The main reasons for the rating include: 1) the company released its quarterly report for the year 24; 2) Specifically, domestic mar
Pumen Technology (688389): Performance is in line with expectations, rapid growth in the international market and IVD
Commentary on the 2024 Quarterly Report of Pumen Technology (688389): Performance is in line with expectations, rapid growth in the international market and IVD
Pumen Technology (688389): Net profit to mother increased 21.69% year-on-year, and the medical and aesthetic business accelerated development
Pumen Technology (688389) 2024 Quarterly Report Review: Outstanding International Business Performance, Rapid IVD Growth
Tianfeng Securities released a research report on April 26 stating that it gave Pumen Technology (688389.SH) a buying rating. The main reasons for the rating include: 1) growth in all business segments, and growth in domestic and overseas markets; 2) buil
Commentary on the 2024 Quarterly Report of Pumen Technology (688389): Steady growth under a high base, profit margins slightly exceeded expectations
Pumen Technology (688389): Excellent profit side performance in Q1, significant optimization of profitability
Cinda Securities released a research report on April 22 stating that it gave Pumen Technology (688389.SH) a buying rating. The main reasons for the rating include: 1) the company's business focuses on the two major sectors of in vitro diagnosis and treatm
Pumen Technology (688389): In Vitro Diagnosis+Treatment and Rehabilitation Dual Wheel Drive Medical and Aesthetic Business Accelerates Development
Pacific released a research report on April 8 stating that it gave Pumen Technology (688389.SH) a purchase rating. The main reasons for the rating include: 1) luminescence and saccharification became the main growth engines, and dermatological and aesthet
Pumen Technology (688389) Annual Report Review: Performance Continues to Grow, Dermatology and Aesthetic Products Rise Rapidly
Brief review report of Pumen Technology (688389) Company: Continuous optimization of product structure and significant improvement in profitability
No Data